Trisenox(arsenic trioxide)
Arsenic Trioxide, Trisenox (arsenic trioxide) is a small molecule pharmaceutical. Arsenic trioxide was first approved as Trisenox on 2000-09-25. It is used to treat promyelocytic leukemia acute in the USA. It has been approved in Europe to treat promyelocytic leukemia acute.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Arsenic trioxide, Trisenox (discontinued: Arsenic trioxide, Trisenox)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| arsenic trioxide | ANDA | 2025-11-07 |
| trisenox | New Drug Application | 2025-10-28 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| promyelocytic leukemia acute | — | D015473 | C92.4 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ARSENIC TRIOXIDE, TRISENOX, CEPHALON | |||
| 2025-01-12 | ODE-167 | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9017 | Injection, arsenic trioxide, 1 mg |
Clinical
Clinical Trials
151 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 2 | 1 | 1 | — | — | 4 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | 1 | — | — | 2 |
| Myeloid leukemia | D007951 | — | C92 | 1 | — | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | 2 | — | — | — | 3 |
| Preleukemia | D011289 | — | — | 1 | 2 | — | — | — | 3 |
| Syndrome | D013577 | — | — | 1 | 2 | — | — | — | 3 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 2 | 1 | — | — | — | 2 |
| Glioma | D005910 | EFO_0000520 | — | 2 | 1 | — | — | — | 2 |
| Promyelocytic leukemia acute | D015473 | — | C92.4 | 1 | 1 | — | — | — | 2 |
| Multiple myeloma | D009101 | — | C90.0 | 2 | 1 | — | — | — | 2 |
| Plasma cell neoplasms | D054219 | — | — | 2 | 1 | — | — | — | 2 |
| Lung neoplasms | D008175 | — | C34.90 | — | 1 | — | — | — | 1 |
| Small cell carcinoma | D018288 | — | — | — | 1 | — | — | — | 1 |
Show 7 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Essential thrombocythemia | D013920 | — | D47.3 | 1 | — | — | — | — | 1 |
| Polycythemia vera | D011087 | — | D45 | 1 | — | — | — | — | 1 |
| Primary myelofibrosis | D055728 | — | D47.4 | 1 | — | — | — | — | 1 |
| Thrombocytosis | D013922 | — | D75.83 | 1 | — | — | — | — | 1 |
| Polycythemia | D011086 | EFO_0005804 | D75.1 | 1 | — | — | — | — | 1 |
| Gata2 deficiency | D000077428 | — | D46.22 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Arsenic trioxide |
| INN | — |
| Description | Arsenic trioxide, sold under the brand name Trisenox among others, is an inorganic compound with the formula As2O3. As an industrial chemical, its major uses include the manufacture of wood preservatives, pesticides, and glass. It is also used as a medication to treat a type of cancer known as acute promyelocytic leukemia. For this use it is given by injection into a vein.
|
| Classification | Small molecule |
| Drug class | Antineoplastic agent |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O1[As]2O[As]3O[As]1O[As](O2)O3 |
Identifiers
| PDB | — |
| CAS-ID | 1327-53-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2362016 |
| ChEBI ID | 30621 |
| PubChem CID | 261004 |
| DrugBank | DB01169 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 14,914 documents
View more details
Safety
Black-box Warning
Black-box warning for: Arsenic trioxide, Trisenox
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,385 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use